FierceBiotech Names Arrakis Therapeutics as One of Its “Fierce 15” Biotech Companies of 2018
WALTHAM, Mass.--(BUSINESS WIRE)--Oct 2, 2018--Arrakis Therapeutics today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181002005256/en/
Arrakis is pioneering the discovery of a new class of medicines called RNA-targeted small molecules, or rSMs. Based on new understandings of the structure of RNA, Arrakis is designing rSMs that directly bind and modify the biological function of RNA to treat disease, opening up new therapeutic potential to reach valuable drug targets that are not accessible with today’s medicines.
“We are honored to be selected as a Fierce 15 company and recognized for Arrakis’ pioneering approach to target RNA with small molecule drugs,” said Michael Gilman, PhD, chief executive officer of Arrakis Therapeutics. “This award is a tribute to the fierce commitment of our outstanding team of scientific leaders, employees, and investors who are making it possible for us to transform the way that RNA is targeted and bring innovative treatments to patients.”
“We appreciate the recognition and excitement about Arrakis’ vision to interrogate the vast and largely unexplored transcriptome to identify new disease intervention points that we can target with rSMs,” said Jennifer C. Petter, PhD, Founder and Chief Scientific Officer of Arrakis Therapeutics.
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 16 th annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
About FierceBiotech FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About Arrakis Therapeutics Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today’s medicines. Arrakis is building a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer, and rare genetic diseases. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Mass. Please visit www.arrakistx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005256/en/
Rebecca Willumson, 202-824-5050
For Arrakis Therapeutics
Kathryn Morris, 914-204-6412
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL
SOURCE: Arrakis Therapeutics
Copyright Business Wire 2018.
PUB: 10/02/2018 09:00 AM/DISC: 10/02/2018 09:01 AM